Detalhe da pesquisa
1.
Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia.
Future Oncol;
17(23): 2989-3005, 2021 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34024158
2.
Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center.
Leuk Res;
119: 106885, 2022 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35738024
3.
An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia.
Expert Rev Hematol;
14(5): 407-417, 2021 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34076549
4.
Retrospective Analysis of Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Treated with FLAG at a Comprehensive Cancer Center.
Clin Lymphoma Myeloma Leuk;
21(7): e611-e618, 2021 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33811007
5.
Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center.
Front Oncol;
11: 649209, 2021.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33777810